Biogen

This study tests a new drug, felzartamab, for people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. The goal is to see if felzartamab can lower protein in urine and keep kidneys working better than the current drug,…

This study tests omaveloxolone (SKYCLARYS), a drug already approved for adults with Friedreich's ataxia, in children aged 2 to 15. The goal is to see if it improves balance and stability and is safe for younger patients. About 255 participants will receive either the drug or a pl…

This study tests a drug called salanersen in babies who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug helps the body make more of a protein needed for muscle and nerve function. Researchers want to see if early treatment can prevent or re…

This study tests a new drug called salanersen (BIIB115) in people aged 15 to 60 with spinal muscular atrophy (SMA). The drug aims to help the body produce more of a key protein needed for muscle and nerve function. Participants receive one injection into the spinal fluid each yea…

This study tracks the safety of tofersen (Qalsody) in 12 Chinese adults with a genetic form of ALS (SOD1 mutation). Participants receive 13 doses injected into the spine over one year. The main goal is to see how many people have side effects. This is a post-marketing study, mean…

This study tests a new drug called litifilimab for people with lupus that causes painful or itchy skin rashes (cutaneous lupus). It is for those whose rashes did not improve with standard antimalarial pills. The study will compare the drug to a placebo for 24 weeks, then everyone…

This study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults with protein in thei…

This study tests a drug called felzartamab in 120 kidney transplant patients whose bodies are attacking their new kidney (antibody-mediated rejection). The drug targets immune cells that make harmful antibodies, aiming to stop damage and keep the kidney working. Participants will…

This study tests a drug called felzartamab in 81 kidney transplant recipients who developed microvascular inflammation (MVI), a type of blood vessel injury that can lead to kidney failure. There are no approved treatments for this condition. Participants will receive either felza…

This study looks at how the body handles nusinersen (Spinraza) when given through a new implanted device called ThecaFlex DRx™, compared to a standard lumbar puncture. About 58 people with spinal muscular atrophy who are already in the PIERRE study will take part. Researchers wil…

This study follows 200 people with postpartum depression (PPD) who have a new prescription for zuranolone. Researchers will use online surveys to track changes in depression symptoms 15, 45, and 90 days after starting the medication. The goal is to better understand how symptoms …

This study follows about 1,178 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY®) during pregnancy affects their babies. Researchers will compare birth outcomes among three groups: those who took the drug, those who took other MS drugs…

This study looks at how the drug Spinraza (nusinersen) affects pregnant women with spinal muscular atrophy (SMA) and their babies. Researchers will collect health information from up to 20 pregnant women who took Spinraza before or during pregnancy, without changing their medical…

This study follows 300 people with Friedreich's ataxia who are taking or starting omaveloxolone (SKYCLARYS®). Researchers will collect safety information over up to 5 years, focusing on serious side effects and heart or liver problems. Participants continue their normal care, and…

This early-stage study is testing the safety of a new drug called BIIB142 in 78 healthy adults. Researchers will give increasing doses to find the highest safe amount and see how the body processes the drug. Participants are randomly assigned to receive either BIIB142 or a placeb…

This study looks at the long-term safety of the drug tofersen (Qalsody) in people with a rare, inherited form of ALS called SOD1-ALS. Researchers will collect health information from about 125 participants in Europe and the U.S. over at least 7 years, without changing their medic…

This early-phase study tests the safety of a new drug called BIIB145, which is being developed for multiple sclerosis (MS). Since this is the first time the drug is given to people, it involves 104 healthy adults to see how the body handles it and if it causes any side effects. P…